India's DCGI Halts Avandia's TIDE Trial Aimed At Proving CV Safety; Steps Up Review of "Controversial Drugs" Sold In India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - GlaxoSmithKline may be temporarily relieved after U.S. FDA's joint advisory committee recommended that GSK's controversial anti-diabetes drug Avandia (rosiglitazone) remain on the market; but dealing with the product seems to be getting tougher for the company in countries like India
You may also be interested in...
As Doctors Mount Pressure On Government, India Bans Diabetes Drug Rosiglitazone In Line With EU Action
MUMBAI - The Drug Controller General of India has banned use of anti-diabetes agent rosiglitazone following a meeting of an expert committee called by the Ministry of Health and Family Welfare to study the safety issues related to the drug
As Doctors Mount Pressure On Government, India Bans Diabetes Drug Rosiglitazone In Line With EU Action
MUMBAI - The Drug Controller General of India has banned use of anti-diabetes agent rosiglitazone following a meeting of an expert committee called by the Ministry of Health and Family Welfare to study the safety issues related to the drug
As More Leading Doctors Oppose Avandia, Will Indian Regulators Propose A Ban?
MUMBAI - Leading Indian doctors have begun speaking out against GlaxoSmithKline's anti-diabetes brand Avandia (rosiglitazone) - branded as Windia in the Indian market - after U.S.FDA restricted the drug's use and European regulatory authorities ordered a complete withdrawal of the medicine from the market